Compare Meta Platforms Inc (META) vs Pfizer Inc (PFE) Price & Performance

META stock trades at $594.92, up 0.48% over 24 hours, with a bearish technical signal driven by moving averages and overbought short-term RSI. The company reported strong Q1 2026 earnings of $10.44 EPS, beating expectations, but missed in Q2 2026. Revenue growth remains robust, with 2025 revenue at $200.97 billion, though net income dipped to $60.46 billion. Recent news highlights the launch of AI model Muse Spark and a legal ruling in Massachusetts over youth addiction claims.

Outlook is mixed: analyst consensus is bullish with a $761.95 price target, citing AI innovations and solid fundamentals, but risks include high capital expenditure, regulatory lawsuits, and competitive pressures. The stock's valuation metrics like P/E of 22.41 suggest room for growth if execution continues, but investors should weigh legal and market volatility concerns.

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.